Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...
Core Operating Margin: 32.6%.
Core Operating Income: EUR1.1 billion, a growth of 10.8%.
Free Cash Flow: EUR774 million, an increase of 8.9%.
Revenue from Ex-Somatuline Portfolio: Grew by 12.2%.
Cabometyx Sales: Increased by 13.3% for the full year.
ONIVYDE Sales: Grew 23.7% for the full year.
Fidrisertib Sales: Rose by 24%.
Dysport Sales Growth: 9.2% for the full year.
Bylvay Sales: EUR136 million.
IQIRVO Sales: EUR22 million.
R&D Costs: Increased by 10.9%, exceeding 20% of sales.
SG&A Costs: Increased by 3.3%, with a ratio to sales at 34.4%.
Net Cash Position: EUR160 million at the end of December.
Dividend Increase: From EUR1.2 to EUR1.4 per share.
Warning! GuruFocus has detected 4 Warning Signs with IPSEF.
Release Date: February 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Ipsen SA (IPSEF) reported a 9.9% increase in total sales for 2024, driven by strong performance in their ex-somatuline portfolio.
The company achieved a core operating margin of 32.6%, reflecting efficient cost management and strong sales performance.
Ipsen SA (IPSEF) received a positive FDA decision for ONIVYDE in first-line pancreatic ductal adenocarcinoma, with subsequent approvals in the US and EU.
The company anticipates significant pipeline milestones in 2025, including potential approvals for Cabometyx in neuroendocrine tumors and Tovorafenib in Europe.
Ipsen SA (IPSEF) has a strong balance sheet with no debt and EUR 2.3 billion available for external innovation, indicating financial stability and capacity for growth.
Ipsen SA (IPSEF) faces increased competition and pricing pressure for Cabometyx in Europe and China, impacting sales growth.
The company recognized an impairment loss of EUR 281 million related to Sohonos due to lower-than-anticipated patient uptake.
Somatuline is expected to face accelerated erosion due to increased generic competition, impacting profitability.
The aesthetics market in the US is experiencing some softening, which could affect future growth prospects for Dysport.
Ipsen SA (IPSEF) anticipates a contraction in core operating profit margin in 2025 due to increased R&D expenses and competitive pressures.
Q: Could you provide more details on the expected erosion pattern for Somatuline in 2025 and the current state of generic competition in Europe and the US? A: David Loew, CEO: The erosion pattern for Somatuline is expected to accelerate compared to historical levels due to anticipated market entry by additional generics, likely around mid-year. In Europe and the US, we have seen significant shortages from existing generics, but we expect increased competition and accelerated erosion moving forward.
Q: Can you explain the drivers behind the expected margin contraction in 2025 and how it will phase between H1 and H2? A: Aymeric le Chatelier, CFO: The margin contraction is primarily due to increased erosion from Somatuline and continued investment in R&D and SG&A to support ongoing and future launches. H1 margins will be higher due to lower costs and less impact from generics, while H2 will see more erosion and investment, leading to lower margins.
Q: How is the launch of IQIRVO progressing, and what are the competitive dynamics in the market? A: David Loew, CEO: The IQIRVO launch is progressing well, with most patients being de novo second-line. We are seeing good feedback from prescribers despite competition from Gilead. We have increased our field force and presented new data on fatigue, which affects 80% of PBC patients.
Q: What is the current market share for ONIVYDE in first-line pancreatic cancer, and what is the potential for growth in the community setting? A: David Loew, CEO: ONIVYDE is used by 32% of large academic centers, with growth primarily from the first-line setting. The patient flow is about 50-50 between academic and community settings, indicating significant potential for growth in community practices.
Q: What are your expectations for the growth trajectory of IQIRVO in 2025, and how does it compare to Gilead's product? A: David Loew, CEO: We anticipate market expansion and are sticking to our peak sales guidance for IQIRVO. While we can't comment on Gilead's trajectory, we are pleased with our current uptake and expect continued growth.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
LVMH downgraded to Market Perform from Outperform at CICC
CICC downgraded LVMH (LVMUY) to Market Perform from Outperform with a EUR 480 price target Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Upturn
2 days ago
- Business Upturn
WNS Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Shareholders Vote 'FOR' Proposed Acquisition by Capgemini
WNS (Holdings) Limited (NYSE: WNS) ('WNS' or the 'Company'), a digital-led business transformation and services company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ('ISS') and Glass, Lewis & Co. ('Glass Lewis') have each recommended that shareholders vote 'FOR' the previously announced acquisition of the Company by Capgemini SE (EUR: CAP) ('Capgemini'). The 'FOR' recommendations apply to both proxy voting proposals to be considered at the upcoming Court Meeting and General Meeting of Shareholders ('General Meeting'), each scheduled for August 29, 2025. Business Wire India WNS (Holdings) Limited (NYSE: WNS) ('WNS' or the 'Company'), a digital-led business transformation and services company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ('ISS') and Glass, Lewis & Co. ('Glass Lewis') have each recommended that shareholders vote 'FOR' the previously announced acquisition of the Company by Capgemini SE (EUR: CAP) ('Capgemini'). The 'FOR' recommendations apply to both proxy voting proposals to be considered at the upcoming Court Meeting and General Meeting of Shareholders ('General Meeting'), each scheduled for August 29, 2025. As previously announced on July 7, 2025, WNS and Capgemini entered into a definitive transaction agreement pursuant to which Capgemini will acquire WNS for a cash consideration of $76.50 per WNS share. The total cash consideration will amount to $3.3 billion, excluding WNS net financial debt. The transaction remains on track to close prior to the end of the calendar year, subject to the satisfaction of customary closing conditions and regulatory approvals. ISS and Glass Lewis have reviewed the proposed transaction and determined that it is in the best interests of WNS shareholders. Both firms cited the Company's evaluation of alternative proposals and implied share price premium as key factors in establishing their 'FOR' recommendations.1 WNS' Board of Directors has also unanimously recommended that shareholders vote 'FOR' this strategic combination at both the upcoming Court Meeting and General Meeting. Shareholders are encouraged to vote as soon as possible. The Company's shareholders are reminded that their vote is extremely important, no matter how many shares they own. Actions to be Taken WNS Shareholders are requested to complete and sign the Forms of Proxy in accordance with the instructions printed thereon and return them to WNS' registered office at 22 Grenville Street, St Helier, Jersey JE4 8PX, Channel Islands (Attn: Mourant Secretaries (Jersey) Limited), so as to be received as soon as possible and in any event not later than 2.00 p.m. (London Time) on August 27, 2025 (in the case of the Court Meeting) or 2.15 p.m. (London Time) on August 27, 2025 (in the case of the General Meeting). WNS Shareholders may also vote online following the instructions set out in the Forms of Proxy, instead of submitting the relevant Forms of Proxy by mail. Votes submitted online must be received not later than 2.00 p.m. (London Time) on August 27, 2025 (in the case of the Court Meeting) or 2.15 p.m. (London Time) on August 27, 2025 (in the case of the General Meeting). It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair representation of the opinion of WNS Shareholders. Whether or not you intend to attend and/or vote at the Court Meeting in person, WNS Shareholders are strongly advised to sign and return your Form of Proxy for the Court Meeting (or vote online) as soon as possible and in any event prior to 2.00 p.m. (London Time) on August 27, 2025. Registered Shareholders should follow the voting instructions provided by WNS, as described above, while Beneficial Holders should follow the instructions provided by their broker or other intermediary to ensure their vote is counted. 1Permission to cite ISS and Glass Lewis was neither sought nor obtained. Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
2 days ago
- Yahoo
WNS Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Shareholders Vote "FOR" Proposed Acquisition by Capgemini
NEW YORK & LONDON & MUMBAI, India, August 19, 2025--(BUSINESS WIRE)--WNS (Holdings) Limited (NYSE: WNS) ("WNS" or the "Company"), a digital-led business transformation and services company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co. ("Glass Lewis") have each recommended that shareholders vote "FOR" the previously announced acquisition of the Company by Capgemini SE (EUR: CAP) ("Capgemini"). The "FOR" recommendations apply to both proxy voting proposals to be considered at the upcoming Court Meeting and General Meeting of Shareholders ("General Meeting"), each scheduled for August 29, 2025. As previously announced on July 7, 2025, WNS and Capgemini entered into a definitive transaction agreement pursuant to which Capgemini will acquire WNS for a cash consideration of $76.50 per WNS share. The total cash consideration will amount to $3.3 billion, excluding WNS net financial debt. The transaction remains on track to close prior to the end of the calendar year, subject to the satisfaction of customary closing conditions and regulatory approvals. ISS and Glass Lewis have reviewed the proposed transaction and determined that it is in the best interests of WNS shareholders. Both firms cited the Company's evaluation of alternative proposals and implied share price premium as key factors in establishing their "FOR" recommendations.1 WNS' Board of Directors has also unanimously recommended that shareholders vote "FOR" this strategic combination at both the upcoming Court Meeting and General Meeting. Shareholders are encouraged to vote as soon as possible. The Company's shareholders are reminded that their vote is extremely important, no matter how many shares they own. Actions to be Taken WNS Shareholders are requested to complete and sign the Forms of Proxy in accordance with the instructions printed thereon and return them to WNS' registered office at 22 Grenville Street, St Helier, Jersey JE4 8PX, Channel Islands (Attn: Mourant Secretaries (Jersey) Limited), so as to be received as soon as possible and in any event not later than 2.00 p.m. (London Time) on August 27, 2025 (in the case of the Court Meeting) or 2.15 p.m. (London Time) on August 27, 2025 (in the case of the General Meeting). WNS Shareholders may also vote online following the instructions set out in the Forms of Proxy, instead of submitting the relevant Forms of Proxy by mail. Votes submitted online must be received not later than 2.00 p.m. (London Time) on August 27, 2025 (in the case of the Court Meeting) or 2.15 p.m. (London Time) on August 27, 2025 (in the case of the General Meeting). It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair representation of the opinion of WNS Shareholders. Whether or not you intend to attend and/or vote at the Court Meeting in person, WNS Shareholders are strongly advised to sign and return your Form of Proxy for the Court Meeting (or vote online) as soon as possible and in any event prior to 2.00 p.m. (London Time) on August 27, 2025. Registered Shareholders should follow the voting instructions provided by WNS, as described above, while Beneficial Holders should follow the instructions provided by their broker or other intermediary to ensure their vote is counted. 1Permission to cite ISS and Glass Lewis was neither sought nor obtained. About WNS WNS (Holdings) Limited (NYSE: WNS) is a digital-led business transformation and services company. WNS combines deep domain expertise with talent, technology, and AI to co-create innovative solutions for over 700 clients across various industries. WNS delivers an entire spectrum of solutions including industry-specific offerings, customer experience services, finance and accounting, human resources, procurement, and research and analytics to re-imagine the digital future of businesses. As of June 30, 2025, WNS had 66,085 professionals across 65 delivery centers worldwide including facilities in Canada, China, Costa Rica, India, Malaysia, the Philippines, Poland, Romania, South Africa, Sri Lanka, Turkey, the United Kingdom, and the United States. For more information, visit or follow us on Facebook, Twitter, and LinkedIn. Safe Harbor Provision This document includes certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the US Securities Act, as amended, and Section 21E of the US Exchange Act. These forward-looking statements generally include statements related to the Acquisition, including the timing of completion of the Acquisition. These forward-looking statements are based on WNS' current expectations, estimates and projections regarding, among other things, the expected date of closing and the potential benefits of the Acquisition, WNS' business and industry, and management's beliefs and certain assumptions made by WNS, all of which are subject to change. Forward-looking statements often contain words such as "expect," "anticipate," "intend," "aims," "plan," "believe," "could," "seek," "see," "will," "may," "would," "might," "considered," "potential," "estimate," "continue," "likely," "expect," "target," "project," or similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include but are not limited to: the Acquisition will not be consummated on a timely basis or at all; the possibility that any or all of the various conditions to the consummation of the Acquisition may not be satisfied or waived, including the failure to receive the required shareholder approval for the scheme or any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); the occurrence of any event, change or other circumstance that could give rise to the termination of the Transaction Agreement; the effect of the announcement or pendency of the Acquisition on the Company's business relationships, operating results, and business generally; risks that the Acquisition disrupts the Company's current plans and operations; potential difficulties in WNS' employee retention as a result of the proposed transaction; there may be liabilities that are not known, probable or estimable at this time or unexpected costs, charges or expenses; the Acquisition may result in the diversion of management's time and attention to issues relating to the Acquisition; there may be significant transaction costs in connection with the Acquisition; unfavorable outcome of legal proceedings that may be instituted against WNS following the announcement of the Acquisition; and the risk that WNS' stock price may decline significantly if the Acquisition is not consummated. These risks, as well as other risks associated with the Acquisition, are more fully discussed in the Scheme Document. In addition, a number of important factors could cause WNS' actual future results and other future circumstances to differ materially from those expressed in any forward-looking statements, including but not limited to those important factors discussed in Part I, Item 1A "Risk Factors" in WNS' Annual Report on Form 10-K for the fiscal year ended March 31, 2025, as any such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC's website at and WNS' investor relations site at These forward-looking statements speak only as of the date they are made, and, except as may be required under applicable law, WNS undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts Investors:David Mackey EVP–Finance & Head of Investor RelationsWNS (Holdings) Limited+1 (646) Media: Archana Raghuram EVP & Global Head–Marketing & CommunicationsWNS (Holdings) Limited+91 (22) 4095 pr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
